[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Equilyse [@equilyse1](/creator/twitter/equilyse1) on x XXX followers Created: 2025-07-23 11:38:06 UTC $DHR: Danaher reported solid Q2 2025 results—1.5% core revenue growth to $5.9B, a XXXX% adjusted operating profit margin, and adjusted EPS of $1.80, up X% YOY. Free cash flow was strong at $1.1B for the quarter. Full-year core revenue growth is expected to be approximately 3%, with adjusted diluted net EPS guidance raised to $7.70-$7.80. Matt Gugino will succeed Matt McGrew as CFO at the end of February 2026. Bioprocessing shines with high single-digit growth, driven by consumables for commercialized therapies, while life sciences saw a XXX% core revenue decrease but expects a positive low single-digit recovery in the second half. Diagnostics grew 2%, led by Beckman Coulter Diagnostics, with Cepheid experiencing double-digit non-respiratory revenue growth. The company reaffirmed its belief that bioprocessing is a high single-digit grower in both 2025 and the long term. Global trade tensions and tariffs pose challenges, with an estimated $200M exposure. China saw a mid-single-digit decline, offset by growth elsewhere. Danaher is targeting $150M in structural cost reductions and views AI as a potential tailwind for drug development.  XX engagements  **Related Topics** [$11b](/topic/$11b) [cash flow](/topic/cash-flow) [eps](/topic/eps) [$59b](/topic/$59b) [quarterly earnings](/topic/quarterly-earnings) [$dhr](/topic/$dhr) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/equilyse1/status/1947984565659738159)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Equilyse @equilyse1 on x XXX followers
Created: 2025-07-23 11:38:06 UTC
$DHR: Danaher reported solid Q2 2025 results—1.5% core revenue growth to $5.9B, a XXXX% adjusted operating profit margin, and adjusted EPS of $1.80, up X% YOY. Free cash flow was strong at $1.1B for the quarter. Full-year core revenue growth is expected to be approximately 3%, with adjusted diluted net EPS guidance raised to $7.70-$7.80. Matt Gugino will succeed Matt McGrew as CFO at the end of February 2026.
Bioprocessing shines with high single-digit growth, driven by consumables for commercialized therapies, while life sciences saw a XXX% core revenue decrease but expects a positive low single-digit recovery in the second half. Diagnostics grew 2%, led by Beckman Coulter Diagnostics, with Cepheid experiencing double-digit non-respiratory revenue growth. The company reaffirmed its belief that bioprocessing is a high single-digit grower in both 2025 and the long term.
Global trade tensions and tariffs pose challenges, with an estimated $200M exposure. China saw a mid-single-digit decline, offset by growth elsewhere. Danaher is targeting $150M in structural cost reductions and views AI as a potential tailwind for drug development.
XX engagements
Related Topics $11b cash flow eps $59b quarterly earnings $dhr stocks healthcare